Vice President, Clinical DevelopmentVega Therapeutics Inc.South San Francisco, California, United States
PB1110 - VGA039, a novel anti-Protein S antibody, enhances ex vivo coagulation with hemophilia A blood as assessed by thromboelastometry
Tuesday, June 25, 202413:45 – 14:45 ICT
OC 73.3 - VGA039, a Protein S-targeting monoclonal antibody, demonstrates in a Phase Ia healthy volunteer trial the potential of subcutaneous weekly or less frequent prophylactic dosing for bleeding disorders
Wednesday, June 26, 202410:45 – 11:00 ICT
